Respiratory syncytial virus is the second most common cause of infant mortality and a major
cause of morbidity and mortality in older adults (aged> 60 years). Efforts to develop a …

Over the past several decades, messenger RNA (mRNA) vaccines have progressed from a
scepticism-inducing idea to clinical reality. In 2020, the COVID-19 pandemic catalysed the …

Background Respiratory syncytial virus (RSV) is an important cause of acute respiratory
infection, lower respiratory tract disease, clinical complications, and death in older adults …

Background Respiratory syncytial virus (RSV) can cause substantial morbidity and mortality
among older adults. An mRNA-based RSV vaccine, mRNA-1345, encoding the stabilized …

Monoclonal antibodies (mAbs) are appealing as potential therapeutics and prophylactics for
viral infections owing to characteristics such as their high specificity and their ability to …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emerging virus that is
highly pathogenic and has caused the recent worldwide pandemic officially named …

The development of effective vaccines to combat infectious diseases is a complex multi-year
and multi-stakeholder process. To accelerate the development of vaccines for coronavirus …

The large global burden of respiratory syncytial virus (RSV) respiratory tract infections in
young children and older adults has gained increased recognition in recent years. Recent …

A vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is needed to
control the coronavirus disease 2019 (COVID-19) global pandemic. Structural studies have …

The coronavirus disease 2019 (COVID-19) pandemic has led to accelerated efforts to
develop therapeutics and vaccines. A key target of these efforts is the spike (S) protein …